Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?-Reference-Cited by-同舟云学术

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Published:2011-11-17 Issue:12 Volume:20 Page:1030-1032
ISSN:0906-6705
Container-title:Experimental Dermatology
language:en
Short-container-title:

Author:

Passeron Thierry,Lacour Jean-Philippe,Allegra Maryline,Ségalen Coralie,Deville Anne,Thyss Antoine,Giacchero Damien,Ortonne Jean-Paul,Bertolotto Corine,Ballotti Robert,Bahadoran Philippe

Publisher

Wiley

Subject

Dermatology,Molecular Biology,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0625.2011.01385.x/fullpdf

Reference14 articles.

1. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

3. Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

4. Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

5. In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene;Melanoma Research;2023-03-03

2. Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review;Anticancer Research;2021-12-29

3. BRAF fusion Spitz neoplasms; clinical morphological, and genomic findings in six cases;Journal of Cutaneous Pathology;2020-09-14

4. Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’;Journal of Clinical Pathology;2019-12-18

5. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses;Cell Reports;2019-10